← Human Trials & Peer-Reviewed Studies
The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial
Plain-language guide to PMID 17365753 (2007): double-blind randomized controlled trial study of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 17365753
- Journal
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- David SP et al. (5 authors)
- DOI
- 10.1080/14622200601078566
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
The study setting was a primary care research network in Oxfordshire, United Kingdom.
The primary outcome measures were biochemically verified sustained abstinence from cigarette smoking at end of treatment and 24-week follow-up.
Who Took Part
By PubMed's age tags, the people studied were adults, both men and women.
In this follow-up of a randomized placebo-controlled clinical trial of nicotine replacement transdermal patch for smoking cessation, 741 smokers of European ancestry who were randomized to receive active patch or placebo patch were genotyped for the serotonin transporter gene-linked polymorphic region.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.
What Was Measured
The study setting was a primary care research network in Oxfordshire, United Kingdom.
The primary outcome measures were biochemically verified sustained abstinence from cigarette smoking at end of treatment and 24-week follow-up.
PubMed files the paper under topics including Nicotine, Polymorphism, Genetic, Serotonin Plasma Membrane Transport Proteins, Smoking and Smoking Cessation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).
The publication is from 2007 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.